Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IIa trial of AGS 003 for the treatment of early stage renal cell carcinoma following nephrectomy

Trial Profile

Phase IIa trial of AGS 003 for the treatment of early stage renal cell carcinoma following nephrectomy

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 30 Mar 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rocapuldencel-T (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 May 2014 New trial record
    • 13 May 2014 Argos Therapeutics intends to devote its cash, cash equivalents and short term investments to fund its planned phase 2 clinical trial of AGS 003 in early stage RCC prior to and following nephrectomy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top